Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
6.34
+0.13 (2.09%)
At close: Jun 26, 2026, 4:00 PM EDT
6.26
-0.08 (-1.22%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Taysha Gene Therapies Revenue
Taysha Gene Therapies had revenue of $7.47M in the twelve months ending March 31, 2026, up 3.42% year-over-year. In the year 2025, Taysha Gene Therapies had annual revenue of $9.77M with 17.28% growth.
Revenue (ttm)
$7.47M
Revenue Growth
+3.42%
P/S Ratio
271.44
Revenue / Employee
$75,465
Employees
99
Market Cap
2.03B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.77M | 1.44M | 17.28% |
| Dec 31, 2024 | 8.33M | -7.12M | -46.07% |
| Dec 31, 2023 | 15.45M | 12.95M | 517.55% |
| Dec 31, 2022 | 2.50M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.18B |
| Lakefront Biotherapeutics NV | 1.20B |
| Innoviva | 420.69M |
| AnaptysBio | 232.39M |
| Syndax Pharmaceuticals | 217.17M |
| Zymeworks | 81.26M |
| Monte Rosa Therapeutics | 42.95M |
| Absci | 1.84M |
TSHA News
- 1 day ago - Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting - GlobeNewsWire
- 1 day ago - Taysha Gene Therapies management to meet with Piper Sandler - TheFly
- 2 days ago - Taysha Gene Therapies 32.5M share Spot Secondary priced at $6.00 - TheFly
- 2 days ago - Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 days ago - Taysha Gene Therapies announces $200M common stock offering - TheFly
- 2 days ago - Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 3 days ago - Taysha Gene Therapies price target raised to $14 from $10 at BMO Capital - TheFly
- 3 days ago - Taysha Gene Therapies price target raised to $14 from $10 at BMO Capital - TheFly